During the corresponding time, Prophase Labs Inc saw a revenue deteriorated by -18.93 % year on year, sequentially revenue grew by 111.51 %. While revenue at the Prophase Labs Inc 's corporate clients
Prophase Labs Inc's Comment on Sales, Marketing and Customers
The company operates through its wholly owned subsidiaries, including Nebula and ProPhase Diagnostics. Nebula offers sequencing services and operates DNA Expand, a platform that allows consumers to upload DNA data from other providers to receive health and wellness reports based on genetic variants. DNA Expand's database includes whole genome sequencing data from tests conducted in 130 countries. Nebula Genomics specializes in genomics testing technologies to analyze entire genomes for identifying inherited disorders, disease risk, drug response, and genetic mutations.
ProPhase Diagnostics provided COVID-19 clinical diagnostic and testing services, including PCR and rapid antigen tests, at CLIA-certified laboratories in New Jersey and New York. Following decreased demand and reimbursement changes after the expiration of the federal Public Health Emergency, ProPhase ceased diagnostic testing services in late 2024 and filed for Chapter 11 bankruptcy in 2025 to focus on reorganization and collection of accounts receivable.
The company's filings reference customers and markets associated with Nebula, Nebula Genomics, ProPhase Diagnostics, ProPhase Diagnostics NJ, Inc., and ProPhase Diagnostics NY, Inc.
Prophase Labs Inc’s Comment on Sales, Marketing and Customers
The company operates through its wholly owned subsidiaries, including Nebula and ProPhase Diagnostics. Nebula offers sequencing services and operates DNA Expand, a platform that allows consumers to upload DNA data from other providers to receive health and wellness reports based on genetic variants. DNA Expand's database includes whole genome sequencing data from tests conducted in 130 countries. Nebula Genomics specializes in genomics testing technologies to analyze entire genomes for identifying inherited disorders, disease risk, drug response, and genetic mutations.
ProPhase Diagnostics provided COVID-19 clinical diagnostic and testing services, including PCR and rapid antigen tests, at CLIA-certified laboratories in New Jersey and New York. Following decreased demand and reimbursement changes after the expiration of the federal Public Health Emergency, ProPhase ceased diagnostic testing services in late 2024 and filed for Chapter 11 bankruptcy in 2025 to focus on reorganization and collection of accounts receivable.
The company's filings reference customers and markets associated with Nebula, Nebula Genomics, ProPhase Diagnostics, ProPhase Diagnostics NJ, Inc., and ProPhase Diagnostics NY, Inc.
Sources:
Prophase Labs Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Prophase Labs Inc’s corporate clients.
For your research, we’ve provided 9 tables on Prophase Labs Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
215.63 %